BidaskClub cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report released on Wednesday morning.

SUPN has been the topic of several other reports. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a hold rating to a strong sell rating in a report on Thursday, October 11th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a report on Monday, August 13th. Mizuho started coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a buy rating and a $61.00 price objective on the stock. Cantor Fitzgerald set a $56.00 price target on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Thursday, October 4th. Finally, Jefferies Financial Group upped their price target on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a buy rating in a research note on Thursday, August 9th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $54.78.

Shares of NASDAQ:SUPN traded down $0.29 on Wednesday, hitting $45.27. The company had a trading volume of 418,478 shares, compared to its average volume of 616,053. Supernus Pharmaceuticals has a 1-year low of $34.90 and a 1-year high of $61.25. The company has a market cap of $2.36 billion, a P/E ratio of 35.93 and a beta of 0.92. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The firm had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. During the same period in the previous year, the company earned $0.29 earnings per share. The company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, equities research analysts expect that Supernus Pharmaceuticals will post 1.88 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in SUPN. D.A. Davidson & CO. lifted its position in Supernus Pharmaceuticals by 5.6% during the second quarter. D.A. Davidson & CO. now owns 17,369 shares of the specialty pharmaceutical company’s stock worth $1,040,000 after purchasing an additional 921 shares during the period. Amalgamated Bank lifted its position in Supernus Pharmaceuticals by 14.7% during the second quarter. Amalgamated Bank now owns 8,007 shares of the specialty pharmaceutical company’s stock worth $479,000 after purchasing an additional 1,028 shares during the period. First Republic Investment Management Inc. lifted its position in Supernus Pharmaceuticals by 10.3% during the second quarter. First Republic Investment Management Inc. now owns 12,572 shares of the specialty pharmaceutical company’s stock worth $753,000 after purchasing an additional 1,179 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after purchasing an additional 1,251 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Supernus Pharmaceuticals by 13.8% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,465 shares of the specialty pharmaceutical company’s stock worth $628,000 after purchasing an additional 1,509 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Recommended Story: Preferred Stock

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.